Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Restructuring Costs (2020 - 2024)

Bioventus' Restructuring Costs history spans 5 years, with the latest figure at -$52000.0 for Q4 2024.

  • For Q4 2024, Restructuring Costs rose 26.76% year-over-year to -$52000.0; the TTM value through Dec 2024 reached -$52000.0, down 106.19%, while the annual FY2025 figure was $2.2 million, 4398.08% up from the prior year.
  • Restructuring Costs reached -$52000.0 in Q4 2024 per BVS's latest filing, up from -$71000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $4.6 million in Q4 2022 to a low of -$71000.0 in Q4 2023.
  • Average Restructuring Costs over 5 years is $884750.0, with a median of $576000.0 recorded in 2022.
  • Peak YoY movement for Restructuring Costs: soared 570.54% in 2022, then tumbled 104.52% in 2023.
  • A 5-year view of Restructuring Costs shows it stood at $563000.0 in 2020, then increased by 22.38% to $689000.0 in 2021, then skyrocketed by 570.54% to $4.6 million in 2022, then plummeted by 101.54% to -$71000.0 in 2023, then rose by 26.76% to -$52000.0 in 2024.
  • Per Business Quant, the three most recent readings for BVS's Restructuring Costs are -$52000.0 (Q4 2024), -$71000.0 (Q4 2023), and -$26000.0 (Q3 2023).